MedTrace Logo

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

NCT05849129 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-01-23

No results posted yet for this study

Summary

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

Conditions

Interventions

DRUG

Ascorbic acid

High dose ascorbic acid delivered intravenously

OTHER

Normal Saline

0.9% NaCl solution

Sponsors & Collaborators

  • Ottawa Hospital Research Institiute

    collaborator UNKNOWN

  • The Canadian College of Naturopathic Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2030-10-01
Completion
2031-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849129 on ClinicalTrials.gov